BELL-ID
24.3.2015 13:21:01 CET | Business Wire | Pressemeddelelse
Host card emulation (HCE) mobile payments specialist, Bell ID, today announces that significant recent growth has seen the company strengthen its global position in the mobile payments market. The launch of its HCE and token service provider (TSP) tokenization solutions has further driven team expansion, requiring investment in new, larger offices for its Rotterdam headquarters.
Growth drives expansion
With HCE and tokenization projects in operation in the market, Bell ID has received significant demand for its products from both banks and service providers. The company has seen a 75% growth year-on-year in orders, driven by a substantial rise in the number of new customers, with 90% of all new orders and requests for proposals focusing on mobile solutions.
The expansion of the business has also required growth in team headcount, with additional support added across all areas of the business. In order to accommodate and facilitate this growth, Bell ID has invested in larger office facilities in Rotterdam, the Netherlands.
Google triggered a year of mobile payments innovation
“Google’s inclusion of HCE in Android KitKat 4.4 kicked off a period of intense activity and innovation in mobile payments,” comments, Pat Curran, Executive Chairman of Bell ID. “The payment schemes confirmed support for HCE and payment tokenization with the development of specifications and, in 2014, EMVCo came forward to define the role of the token service provider. And the bar was raised with the launch of Apple Pay. We were ahead of the curve and were among the first to launch a HCE and tokenization mobile payments platform. We are now seeing the benefits of our hard work with many live implementations worldwide today.”
Trust and innovation are the key
“This is a great moment for Bell ID,” adds Pat. “We have grown with the industry, carrying smart card expertise gained since 1993 into our mobile payments, HCE and tokenization solutions. It is this trust and experience, combined with the technical innovation behind our latest solutions that is creating this demand. We are now positioned for more growth over the coming years and have a strong, experienced team in place to drive further mobile payments advancements in 2015 and beyond.”
Bell ID’s headquarters in Rotterdam supports the regional Bell ID offices in Canada, United States, United Kingdom, Bahrain and Australia. Bell ID operates across the mobile near field communication, EMV, identity and transit markets.
Download Bell ID’s free eBook, ‘Host Card Emulation – NFC’s Missing Link’ or watch its explanatory videos , including HCE, tokenization and TSP.
-ENDS-
Contact:
iseepr
Rob Peryer
rob@iseepr.co.uk
+
44 (0) 1943 468007
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum